We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.21%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.06B
AUM Growth
-$395M
Cap. Flow
-$256M
Cap. Flow %
-5.05%
Top 10 Hldgs %
43.96%
Holding
127
New
13
Increased
22
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
ITGR icon
Integer Holdings
ITGR
+$40.8M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$39.5M
3
EXAS
Exact Sciences
EXAS
+$29.3M
4
ARGX icon
argenx
ARGX
+$22M
5
AMGN icon
Amgen
AMGN
+$21M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$106M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
3
JANX icon
Janux Therapeutics
JANX
+$60.8M
4
ESPR
Esperion Therapeutics
ESPR
+$36.7M
5
SRRK icon
Scholar Rock
SRRK
+$30.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 6.71%
2,718,735
– –
LLY icon
2
Eli Lilly
LLY
$1.09T
$306M 6.04%
337,600
-23,200
-6% -$18.6M
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.32B
$271M 5.34%
15,021,721
– –
BSX icon
4
Boston Scientific
BSX
$68.8B
$252M 4.98%
3,273,000
– –
ISRG icon
5
Intuitive Surgical
ISRG
$128B
$219M 4.33%
493,100
– –
BIIB icon
6
Biogen
BIIB
$31.9B
$209M 4.12%
900,900
– –
ELVN icon
7
Enliven Therapeutics
ELVN
$3.76B
$186M 3.67%
7,959,538
-1,038,800
-12% -$21.9M
MRK icon
8
Merck
MRK
$324B
$163M 3.22%
1,316,000
– –
THC icon
9
Tenet Healthcare
THC
$22.3B
$156M 3.08%
1,173,300
– –
JANX icon
10
Janux Therapeutics
JANX
$898M
$125M 2.46%
2,979,828
-1,295,725
-30% -$60.8M
IONS icon
11
Ionis Pharmaceuticals
IONS
$9.11B
$113M 2.23%
2,372,333
+359,300
+18% +$14.7M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.62B
$102M 2.02%
646,000
-51,500
-7% -$6.62M
SYK icon
13
Stryker
SYK
$134B
$91.5M 1.81%
269,000
– –
ELV icon
14
Elevance Health
ELV
$82.7B
$91.1M 1.8%
168,100
– –
ARGX icon
15
argenx
ARGX
$55.4B
$89.9M 1.78%
209,100
+57,500
+38% +$22M
IRON icon
16
Disc Medicine
IRON
$2.82B
$80.5M 1.59%
1,785,571
+83,334
+5% +$2.83M
SPRY icon
17
ARS Pharmaceuticals
SPRY
$565M
$78.6M 1.55%
9,240,887
– –
THRD
18
DELISTED
Third Harmonic Bio
THRD
$75.1M 1.48%
5,779,071
– –
NTRA icon
19
Natera
NTRA
$36.4B
$74.4M 1.47%
687,500
-211,931
-24% -$21.5M
TMO icon
20
Thermo Fisher Scientific
TMO
$215B
$73M 1.44%
132,000
– –
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$124B
$70.8M 1.4%
151,000
+28,300
+23% +$12.3M
SWTX
22
DELISTED
SpringWorks Therapeutics
SWTX
$64.3M 1.27%
1,707,331
– –
NBIX icon
23
Neurocrine Biosciences
NBIX
$18.3B
$61.7M 1.22%
448,200
+25,100
+6% +$3.44M
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$38.6B
$60.8M 1.2%
+250,300
New +$39.5M
PCVX icon
25
Vaxcyte
PCVX
$7.7B
$60.1M 1.19%
795,900
-270,231
-25% -$18.4M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2024 Portfolio in Review

As of Q2 2024, OrbiMed held 127 positions worth $5.06B, down 7.2% from $5.46B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed withdrew a net $256M in Q2 2024, closing 13 positions and reducing 22 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, OrbiMed opened a new position in Integer Holdings worth $40.4M.

  • OrbiMed's largest Q2 2024 buy was Integer Holdings: 349,221 shares worth $40.4M.
  • OrbiMed added most to Exact Sciences in Q2 2024, an estimated $29.3M increase.
  • OrbiMed's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $104M.
  • OrbiMed fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $106M.
  • OrbiMed's ten largest holdings make up 44% of its $5.06B portfolio in Q2 2024.
  • OrbiMed opened 13 new positions and closed 13 in Q2 2024.
  • OrbiMed's portfolio value fell 7.2% quarter-over-quarter to $5.06B.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.